Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21


A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, Bonnette WG, Gorman SA, Degenhardt Y, Bai Y, McCabe MT, Pappalardi MB, Kasparec J, Tian X, McNulty KC, Rouse M, McDevitt P, Ho T, Crouthamel M, Hart TK, Concha NO, McHugh CF, Miller WH, Dhanak D, Tummino PJ, Carpenter CL, Johnson NW, Hann CL, Kruger RG.

Cancer Cell. 2015 Jul 13;28(1):57-69. doi: 10.1016/j.ccell.2015.06.002.


Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

Wyce A, Degenhardt Y, Bai Y, Le B, Korenchuk S, Crouthame MC, McHugh CF, Vessella R, Creasy CL, Tummino PJ, Barbash O.

Oncotarget. 2013 Dec;4(12):2419-29.


Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.

Mayes PA, Degenhardt YY, Wood A, Toporovskya Y, Diskin SJ, Haglund E, Moy C, Wooster R, Maris JM.

Int J Cancer. 2013 Feb 1;132(3):E149-57. doi: 10.1002/ijc.27781. Epub 2012 Sep 28.


Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).

Liu-Sullivan N, Zhang J, Bakleh A, Marchica J, Li J, Siolas D, Laquerre S, Degenhardt YY, Wooster R, Chang K, Hannon GF, Powers S.

Oncotarget. 2011 Dec;2(12):1254-64.


Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y.

Mol Cancer Ther. 2012 Mar;11(3):720-9. doi: 10.1158/1535-7163.MCT-11-0505. Epub 2011 Dec 14.


Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Qian Y, Hua E, Bisht K, Woditschka S, Skordos KW, Liewehr DJ, Steinberg SM, Brogi E, Akram MM, Killian JK, Edelman DC, Pineda M, Scurci S, Degenhardt YY, Laquerre S, Lampkin TA, Meltzer PS, Camphausen K, Steeg PS, Palmieri D.

Clin Exp Metastasis. 2011 Dec;28(8):899-908. doi: 10.1007/s10585-011-9421-9. Epub 2011 Sep 21.


High chromosome number in hematological cancer cell lines is a negative predictor of response to the inhibition of Aurora B and C by GSK1070916.

Moy C, Oleykowski CA, Plant R, Greshock J, Jing J, Bachman K, Hardwicke MA, Wooster R, Degenhardt Y.

J Transl Med. 2011 Jul 15;9:110. doi: 10.1186/1479-5876-9-110.


Mutation and copy number detection in human cancers using a custom genotyping assay.

Moy C, Aziz MU, Greshock J, Szabo S, McNeil E, Jing J, Conway T, Degenhardt Y, Wooster R, Bachman K.

Genomics. 2011 Oct;98(4):296-301. doi: 10.1016/j.ygeno.2011.04.008. Epub 2011 May 7.


Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.

Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, Testa JR, Nathanson KL, Gimotty PA, Coukos G, Weber BL, Degenhardt Y.

Genes Chromosomes Cancer. 2011 Aug;50(8):606-18. doi: 10.1002/gcc.20883. Epub 2011 May 11.


Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.

Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP.

Clin Cancer Res. 2011 May 15;17(10):3420-30. doi: 10.1158/1078-0432.CCR-10-2946. Epub 2011 Apr 1.


Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.

Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, Zhang X, Bleam M, Halsey W, Hughes A, Moy C, Liu-Sullivan N, Powers S, Bachman K, Jackson J, Weber B, Wooster R.

Mol Cancer Ther. 2010 Jul;9(7):2079-89. doi: 10.1158/1535-7163.MCT-10-0095. Epub 2010 Jun 22.


Molecular target class is predictive of in vitro response profile.

Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, McNeil E, Moy C, Wegrzyn R, Auger K, Hardwicke MA, Wooster R.

Cancer Res. 2010 May 1;70(9):3677-86. doi: 10.1158/0008-5472.CAN-09-3788. Epub 2010 Apr 20.


Targeting Polo-like kinase in cancer therapy.

Degenhardt Y, Lampkin T.

Clin Cancer Res. 2010 Jan 15;16(2):384-9. doi: 10.1158/1078-0432.CCR-09-1380. Epub 2010 Jan 12. Review.


Distinct MHC gene expression patterns during progression of melanoma.

Degenhardt Y, Huang J, Greshock J, Horiates G, Nathanson K, Yang X, Herlyn M, Weber B.

Genes Chromosomes Cancer. 2010 Feb;49(2):144-54. doi: 10.1002/gcc.20728.


High-content analysis of cancer genome DNA alterations.

Degenhardt YY, Wooster R, McCombie RW, Lucito R, Powers S.

Curr Opin Genet Dev. 2008 Feb;18(1):68-72. doi: 10.1016/j.gde.2008.01.005. Epub 2008 Mar 12. Review.


Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.

Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, Gilmer TM.

Cell Prolif. 2007 Aug;40(4):580-94.


Critical role for Daxx in regulating Mdm2.

Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY, El-Deiry WS, Yang X.

Nat Cell Biol. 2006 Aug;8(8):855-62. Epub 2006 Jul 16.


Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1.

van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J, Rong M, Li S, See LH, Nguyen KQ, Hoey T, Wesche H, Powers S.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15901-6. Epub 2005 Oct 24.


Wip1-deficient mice are resistant to common cancer genes.

Harrison M, Li J, Degenhardt Y, Hoey T, Powers S.

Trends Mol Med. 2004 Aug;10(8):359-61. Review.


Gps2, a protein partner for human papillomavirus E6 proteins.

Degenhardt YY, Silverstein SJ.

J Virol. 2001 Jan;75(1):151-60.

Supplemental Content

Loading ...
Support Center